Summary
EU healthcare public procurement exceeds €140 billion annually, making it one of the largest and most complex segments of the public market. The sector spans medical devices subject to the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), pharmaceuticals and vaccines, diagnostic imaging and laboratory equipment, health IT systems, hospital construction and refurbishment, and clinical and support services. Centralised national and regional procurement bodies — AGENAS in Italy, UGAP Santé in France, NHS Supply Chain in Ireland — are concentrating purchasing power and raising the compliance bar. The European Health Data Space (EHDS) Regulation, fully adopted in 2024, is driving a new wave of health IT procurement. Post-pandemic supply chain security requirements and EU strategic health autonomy objectives are reshaping pharmaceutical procurement. This briefing provides the complete intelligence picture for healthcare suppliers in 2026.
Scale and Structure of EU Healthcare Procurement
Healthcare procurement is the EU's third-largest public procurement sector by value, after construction and IT services. The €140+ billion annual figure encompasses procurement by hospitals and health networks, national health services, regional health authorities, university medical centres, and public health agencies. The balance between centralised and decentralised procurement varies significantly by country: France, Italy, and the Nordic states have moved strongly toward centralised purchasing bodies, while Germany remains highly fragmented across Länder, hospital associations, and individual Kreiskliniken.
Procurement volumes in 2026 are elevated by several structural factors. Post-COVID stockpiling mandates — requiring member states to maintain strategic reserves of essential medicines, PPE, and diagnostics — have driven procurement beyond normal consumption levels. The EU Strategic Health Autonomy initiative, launched following supply disruptions during the pandemic, is incentivising near-shoring of pharmaceutical manufacturing and creating new preferred supplier programmes for EU-produced medicines and medical equipment. HERA (the Health Emergency Preparedness and Response Authority) is procuring pandemic preparedness stockpiles and countermeasures centrally.
Medical Device Regulation (MDR) and Procurement Implications
The EU Medical Device Regulation (MDR, 2017/745) has been in full application since May 2021, with transitional provisions for devices with legacy CE certificates extended to 2027 (Class IIb and III) and 2028 (Class IIa and IIb sterile/measuring) following subsequent amendments. For procurement purposes, the critical implication is that contracting authorities are increasingly requiring MDR compliance evidence — not just historical MDD CE marking — as a selection criterion, particularly for high-risk Class IIb and Class III devices.
The In Vitro Diagnostic Regulation (IVDR, 2017/746) has been generating significant procurement disruption in laboratory diagnostics. Many legacy IVD CE certificates are being reclassified under the IVDR at higher risk classes, requiring Notified Body involvement for the first time. Laboratory equipment tenders in 2026 must verify IVDR compliance status and the applicant's Notified Body certification roadmap — suppliers that cannot demonstrate a clear IVDR conformity timeline are increasingly excluded from healthcare framework agreements.
Key CPV codes for medical devices and equipment: 33100000 (medical equipment), 33110000 (imaging equipment for medical, dental, and veterinary use), 33120000 (systems and instruments for cardiac and vascular monitoring), 33140000 (medical consumables), 33150000 (radiotherapy, mechanotherapy, electrotherapy, and physiotherapy devices), 33162000 (theatre equipment), 33190000 (miscellaneous medical devices and products).
Pharmaceutical Procurement in 2026
Pharmaceutical procurement by EU public health systems is governed by a combination of EU procurement law, national pharmaceutical regulations, and increasingly, joint procurement mechanisms. The EU Joint Procurement Agreement — established in 2014 and used extensively for COVID-19 vaccines — allows member states to procure medical countermeasures jointly through the European Commission as central purchasing body. Following pandemic experience, the JPA mechanism has been extended and is now used for broader vaccine procurement (mpox, influenza), novel antibiotics, and pandemic preparedness stockpiles.
At national level, pharmaceutical procurement is conducted by national health insurance funds, hospital pharmacy departments, and regional health authorities using various mechanisms: tendering (for off-patent generics and biosimilars), price negotiation (for patented medicines), and reference pricing (for reimbursement). Suppliers targeting EU pharmaceutical tenders must understand that public payers are actively promoting biosimilar substitution — with several member states mandating biosimilar prescribing or dispensing — creating procurement opportunities in the biosimilar segment while compressing originator biologics prices.
CPV codes for pharmaceuticals: 33600000 (pharmaceutical products), 33610000 (medicinal products for the alimentary tract and metabolism), 33620000 (medicinal products for blood, haematopoietic organs, and cardiovascular system), 33650000 (general anti-infectives for systemic use), 33690000 (various medicinal products).
European Health Data Space and Health IT Procurement
The European Health Data Space (EHDS) Regulation, adopted by the European Parliament in 2024, establishes the legal framework for cross-border health data sharing across the EU. EHDS requires member states to implement MyHealth@EU infrastructure enabling citizens to access and share their electronic health records across borders. For health IT suppliers, EHDS is generating a significant procurement wave: national eHealth agencies and hospital networks are procuring EHDS-compatible EHR systems, patient-facing health data portals, interoperability middleware, and data governance platforms.
EHDS interoperability mandates are based on HL7 FHIR (Fast Healthcare Interoperability Resources) and the European EHR Exchange Format (EEHRxF). Health IT suppliers must be able to demonstrate FHIR R4 compliance in their EHR and health data systems to qualify for new procurement contracts in 2026. Key buyers include national eHealth agencies (e-Health Authority in Estonia, eHealth Denmark, HIE Ireland, Italy's MEF/NSIS), and regional health authorities managing hospital network IT infrastructure upgrades.
CPV codes for health IT: 72200000 (software programming and consultancy), 48814000 (medical information systems), 72310000 (data processing), 72315000 (data management), 79410000 (business and management consultancy, used for health system transformation projects).
Centralised Purchasing Bodies and Framework Agreements
The centralisation of healthcare procurement into national and regional purchasing bodies is one of the defining structural trends of EU healthcare procurement. Key centralised healthcare procurement bodies include: CONSIP/AGENAS (Italy), managing national framework agreements for medical devices, diagnostics, and pharmaceuticals worth billions annually; UGAP Santé (France), operating a catalogue procurement model for hospitals; Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV/INAMI) (Belgium), managing device and pharmaceutical reimbursement; and Zdravotní ústav coordination in Czech Republic and Slovak equivalents across CEE.
Getting onto a national framework agreement is often more valuable than winning individual tenders: it secures a place on multi-year, multi-buyer contracts where hospital procurement departments call off without further competition. Framework applications are highly competitive — evaluation typically assesses technical quality, quality management certification (ISO 13485 for medical devices), post-market surveillance systems, and supply security guarantees.
Key Takeaways
- EU healthcare procurement exceeds €140B annually; post-COVID stockpiling mandates and EU Strategic Health Autonomy are sustaining elevated procurement volumes through 2026.
- MDR and IVDR compliance documentation — including Notified Body certificates and conformity assessment roadmaps — are becoming selection criteria in medical device tenders; legacy MDD certificates alone are insufficient.
- EHDS adoption is driving procurement of FHIR R4-compliant EHR systems, interoperability middleware, and patient health data portals across national eHealth agencies and hospital networks.
- The EU Joint Procurement Agreement is expanding beyond vaccines to broader pandemic preparedness stockpiles and novel antibiotics — creating centralised procurement opportunities alongside national mechanisms.
- National framework agreements (CONSIP, UGAP Santé) are the priority procurement entry point; qualifying requires ISO 13485 certification, post-market surveillance systems, and robust supply security guarantees.